“Anything directly competitive with leronlimab i

“Anything directly competitive with leronlimab in cancer treatments will probably end up losing out.”

This is a strong statement considering leronlimab only has results from 2 patients.

“Looking at their trial in advanced pancreatic cancer an additional 6.4 months of survival doesn't seem like much”

That’s 6.4 months longer than leronlimab has extended the life of a pancreatic cancer patient (none injected yet) and CYDY’s patients on leronlimab haven’t even hit a timeframe where the company can make a statement on extension of life. NP’s MIL was told 3-9 months, so if she lives past the summer, well then, we’re getting somewhere.

Here’s a link to their mTNBC results. The results look good and they already have 9 patients on the drug, with the longest on it for 13 months. They haven’t filed for BTD yet even nor accelerated approval. I point this out because CYDY filed for BTD with data from 4 patients and maybe the longest patient will have been on the leronlimab for 6-7 months at the 60-70 day BTD mark. Also, some on the board have said that leronlimab for mTNBC may be approved for treatment of mTNBC around the time that combo is approved or at least this year. NK’s results in mTNBC are good, they have 9 patients and the trials been ongoing for 13 months, and they don’t have BTD nor have the drug been approved. I think NK’s mTNBC trial is a good comparison and we may be over zealous on our timeframe unless leronlimab works 100% in every patient with few side effects.

https://ir.nantkwest.com/news-releases/news-r...%5Bmin%5D=